← Oncology Approval Tracker

FDA DECISION ·

Rozlytrek

entrectinib · Genentech

Accelerated approvalNew or expanded indicationTumor-agnostic solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For children older than one month with NTRK fusion-positive solid tumors without a known acquired resistance mutation. Tumors must be metastatic or resection likely to cause severe morbidity, with progression after treatment or no satisfactory standard therapy.

LAMPGEN ANALYSIS

Why it matters

The expanded accelerated approval reached younger children, and the FDA also approved an oral pellet formulation.

What research teams should watch

Verify age, fusion and resistance status, then match the formulation to the child's administration needs.

PRIMARY RECORDS

Sources